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TGF-b is pro-metastatic for the late-stage breast cancer cells. Despite recent progress,
the regulation of TGF-b type II receptor remains uncertain. Here we report that FAF1
destabilizes TbRII on the cell surface by recruiting the VCP/E3 ligase complex, thereby
limiting excessive TGF-b response. Importantly, activated AKTdirectly phosphorylates FAF1 at
Ser 582, which disrupts the FAF1–VCP complex and reduces FAF1 at the plasma membrane.
The latter results in an increase in TbRII at the cell surface that promotes both TGF-b-induced
SMAD and non-SMAD signalling. We uncover a metastasis suppressing role for FAF1 through
analyses of FAF1-knockout animals, various in vitro and in vivo models of epithelial-to-
mesenchymal transition and metastasis, an MMTV-PyMT transgenic mouse model of
mammary tumour progression and clinical breast cancer samples. These findings describe a
previously uncharacterized mechanism by which TbRII is tightly controlled. Together, we
reveal how SMAD and AKT pathways interact to confer pro-oncogenic responses to TGF-b.
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T
ransforming growth factor-b (TGF-b) is a pro-metastatic
factor in advanced cancer1–4. Upon ligand binding, the
TGF-b type II serine/threonine kinase receptor (TbRII)
activates the type I receptor (TbRI) to induce SMAD2/3
phosphorylation. Activated SMAD2/3 forms hetero-oligomers
with SMAD4, which accumulate in the nucleus to regulate
target genes1–3. In addition to the canonical SMAD pathway,
TGF-b receptors can initiate other intracellular pathways via
either phosphorylation or direct interaction with signalling
intermediates; these so-called non-SMAD signalling pathways
include several branches that involve phosphatidylinositol kinase
(PI3K)/AKT, mitogen-activated protein kinases (MAPKs) and
Rho-like GTPase signalling intermediates5.
TGF-b cross-talks with other pathways6. Oncogenic PI3K/AKT
signalling antagonizes TGF-b-induced growth arrest and
apoptotic responses7,8. Moreover, high TGF-b levels in tumours
correlate with overactive PI(3)K–AKT signalling, and poor
prognosis in breast cancer9–11. However, how AKT cross-reacts
with TGF-b-induced pro-invasive and pro-metastatic responses
in advanced tumours remains undefined. In the TGF-b/SMAD
canonical pathway, TbRI acts downstream of TbRII; the stability
and membrane localization of TbRII are therefore critical
determinants of both the sensitivity and duration of the TGF-b
response. Many previous studies have concluded that TbRII
mediates the cytostatic effects of TGF-b; loss of its function in
many different cancer models promotes aggressive and metastatic
behaviour12,13. Whether a gain of function in TbRII can promote
metastasis has not been thoroughly investigated. In this work, we
identify FAS-associated factor 1 (FAF1) as a key regulator of cell
surface TbRII, in turn preventing the excessive activation of both
SMAD and non-SMAD TGF-b-induced signalling. During cancer
progression, growth factor-induced (or oncogenic mutation)
activation of AKT mediates FAF1 phosphorylation and its
dissociation from the plasma membrane and TbRII, thereby
reinforcing TbRII stability on the cell surface and activating the
pro-metastatic functions induced by TGF-b in breast cancer cells.
Results
FAF1 associates with TbRII and inhibits TGF-b receptor
signalling. TGF-b can promote invasion and metastasis in
advanced tumours3. Consistent with previous reports14,15, we
observed that breast cancer cells with high metastatic potential
appeared to have elevated TbRII protein levels (Supplementary
Fig. 1a). Upon TbRII depletion, we observed a marked reduction
of both breast cancer and lung cancer metastasis in xenograft
mouse models (Fig. 1a; Supplementary Fig. 1b). Cells isolated
from the metastatic nodules of mice showed a gain in TbRII
protein (but not messenger RNA) expression compared with their
parental cells, suggesting that TbRII protein is stabilized during
cancer metastasis (Fig. 1b). We therefore sought to identify the
critical regulators of TbRII. Treatment with lysosome inhibitors,
such as bafilomycin A1, NH4Cl or chloroquine (but not the
proteasome inhibitors MG132 or lactacystin), led to TbRII
accumulation (Fig. 1c), suggesting that TbRII is degraded via a
lysosomal pathway. We therefore analysed proteins that
co-immunoprecipitated specifically with FLAG-tagged TbRII in
the presence of lysosome inhibitor using mass spectrometry
(Fig. 1d). FAF1, with 12 unique peptides detected, was identified
as the strongest binding partner (Fig. 1d and Supplementary
Table 1; Supplementary Data 1). By using limiting amounts of
TbRII antibody in immunoprecipitation, we pulled down equal
amounts of endogenous TbRII and verified that FAF1 bound to
endogenous TbRII in NH4Cl-treated non-transfected cells
(Fig. 1e). Furthermore, the TGF-b-induced CAGA12-Luc
SMAD-dependent response was inhibited by FAF1 ectopic
expression and was enhanced by the depletion of endogenous
FAF1 (Fig. 1f). These data suggest that FAF1 inhibits TGF-b
signalling by transiently binding to TbRII, which may result in
TbRII instability.
To validate this hypothesis, we first examined whether
FAF1 affects the immediate mediators of TGF-b receptor
signalling. The levels of TGF-b-induced SMAD2 phosphorylation
(P-SMAD2), SMAD2–SMAD4 complex formation, phosphory-
lated AKT (P-AKT) and phosphorylated p38 MAP kinase
(P-p38) were elevated in FAF1-depleted parental MDA-MB-231
cells (Fig. 1g). These responses were severely inhibited by the
ectopic expression of FAF1-WT, but were not affected by a FAF1
mutant lacking the ubiquitin regulatory X (UBX) domain
(Fig. 1h). However, FAF1 did not affect the total levels of
SMAD2, SMAD4, AKT or p38 MAP kinase. These data
suggest that endogenous FAF1 is a critical antagonist for both
TGF-b/SMAD and non-SMAD signalling.
High-grade tumours and/or their cancer-associated fibroblasts
(CAFs) frequently express elevated levels of TGF-b, which
correlates with poor prognosis in cancer patients3,16. Given the
role of FAF1 in restricting TGF-b signalling activity, we
investigated the possibility that loss of FAF1 might be a
relevant prognostic factor in late-stage cancer. Oncomine17
expression analysis revealed FAF1 downregulation in multiple
human cancers in which TGF-b is pro-metastatic (Fig. 1i;
Supplementary Fig. 2a). Using The Cancer Genome Atlas patient
database, we observed that claudin-low breast cancer patients
show significant under-expressed FAF1 (Supplementary Fig. 2b).
In the same database, individuals with breast carcinomas
exhibiting higher FAF1 expression had a longer life expectancy
than those with tumours exhibiting lower FAF1 expression
(Fig. 1j). These data suggest that FAF1 may play a tumour-
suppressing role in multiple human cancer types by inhibiting
tumour-promoting pathways, such as TGF-b signals.
FAF1 promotes turnover of cell surface TbRII. The fact that
depleting endogenous FAF1 enhances the half-life of exogenous
C-terminal HA-tagged TbRII suggests that TbRII protein stability
is highly regulated by FAF1 (Fig. 2a). To confirm this possibility,
we measured the stability of endogenous TbRII. Pulse-chase
labelling experiments showed that endogenous TbRII exhibited a
shortened half-life upon the ectopic expression of FAF1-WT,
but not upon the expression of a FAF1 mutant lacking the UBX
domain (Fig. 2b). Conversely, TbRII displayed a prolonged
half-life in FAF1-depleted cells (Supplementary Fig. 2c). We
therefore investigated whether FAF1 misexpression affects TbRII
levels at the plasma membrane, where signalling is initiated.
Biotin-labelled cell surface TbRII displayed a severely decreased
half-life upon ectopic FAF1 expression, but not upon expression
of a FAF1 mutant lacking the UBX domain (Fig. 2c). As expected,
FAF1 depletion in cells led to higher cell surface TbRII levels and
an apparent decrease in protein turnover (Fig. 2d). These findings
suggest that FAF1 could promote TbRII instability by stimulating
to TbRII turnover at the plasma membrane.
FAF1 recruits VCP/bTRCP to target TbRII for polyubiquitylation.
FAF1 is not an E3 ubiquitin ligase but an adaptor for substrate
ubiquitylation and degradation18–20, and TbRII is regulated
by ubiquitination21. Analysis of the FAF1 interactome by
mass spectroscopy examination of the co-immunoprecipitants
of Flag-tagged FAF1 revealed that FAF1 bound to
valosin-containing protein (VCP) at a ratio near 1:1 (Fig. 3a,b;
Supplementary Data 2). VCP has been shown to interact with the
FAF1 UBX domain18. We found that this UBX domain is
required for FAF1 to antagonize cell surface TbRII (Fig. 2c). This
finding suggests that FAF1 might recruit VCP to regulate TbRII.
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Figure 1 | FAF1 specifically associates with TbRII and inhibits TGF-b signalling. (a) Bioluminescent imaging (BLI) of representative mice from each group
injected into the left heart ventricle with control (Co.) or MDA-MB-231 breast cancer cells stably depleted of TbRII (shTbRII). Images were captured at
week 7. Dorsal images are shown. The BLI signal of every mouse in each experimental group is shown in the middle panel. The percentage of bone
metastasis-free mice (right panel) in each experimental group is given. (b) Immunoblot (IB) analysis of TbRII protein levels in parental (P) and metastatic
(M) variant of MDA-MB-231 and A549 cells (left panel). Quantitative PCR with reverse transcription analyses of TbRII in parental and metastatic cells are
shown (right panel). Data are presented as the mean±s.d. (c) MDA-MB-231 cells were treated with MG132 (25mM), lactacystin (30mM), bafilomycin A1
(1mM), NH4Cl (25mM) or chloroquine (100mM) for 5 h and collected for IB analysis. Actin IB is included as a loading control. (d) Mass spectrometry
results of TbRII-Flag immunoprecipitants in the absence (sample A) and presence (sample B) of NH4Cl (25mM) identified FAF1 as a binding partner;
exemplified peptide is shown in the right panel. (e) IB of the input and immunoprecipitants (IPs) derived from MCF10A-RAS cells treated with NH4Cl
(25mM) as indicated; 5% of the total cell lysate was loaded as input. NS, non-specific antibody. (f) The CAGA12-Luc SMAD-dependent transcriptional
response in HEK293T cells transfected with FAF1 wt/UBX-deleted mutant (mUBX) or shFAF1, as indicated, and treated with TGF-b (5 ngml 1) overnight.
The data are presented as the mean±s.d. of three independent sets of experiments. (g,h) The IBs of total cell lysate (TCL) and anti-SMAD2/3
immunoprecipitants derived from control and FAF1 stable depletion (shFAF1#1 and shFAF1#2) (g) or Myc-FAF1 fl (full length)/UBX-deleted mutant stably
expressing (h) MDA-MB-231 cells treated with ligand at the indicated time points. (i) Oncomine box plots of the FAF1 expression levels in multiple human
advanced cancers versus normal tissues; Po0.01. (j) Kaplan–Meier curves of The Cancer Genome Atlas database showing that the metastasis-free
survival of individuals positively correlated with FAF1 expression by the log-rank test (Po0.01).
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VCP is an evolutionarily conserved hexameric AAA (ATPases
associated with diverse cellular activities) family member that can
convert chemical energy from ATP hydrolysis into mechanical
force to remodel protein complexes22. One such complex—VCP–
ubiquitin fusion degradation 1 (UFD1)–nuclear protein
localization 4 (NPL4)—plays a role in endoplasmic reticulum-
associated degradation22. Other complexes, including VCP-p47
and VCP-UBXD1, have been proposed to catalyse proteasome-
independent membrane trafficking, including membrane protein
segregation22. Interestingly, all of the important VCP-binding
partners were identified among FAF1 co-immunoprecipitants,
including VAPA/VAPB, vesicle-associated membrane proteins
that function in trafficking and membrane fusion, and the E3
ubiquitin ligases b-transducin repeat containing E3 ubiquitin
protein ligase (bTRCP) and Cullin1/3 (Fig. 3a; Supplementary
Data 2). All of these proteins were confirmed to bind FAF1
(Supplementary Fig. 3a).
As examined using a reporter assay, ectopic VCP expression
severely impaired TGF-b/SMAD signalling, whereas knocking
down endogenous VCP enhanced this response (Fig. 3c).
In cells ectopically expressing VCP, TbRII cell surface localization
was lost, and the protein appeared to localize in a dotted
pattern in the cytosol (Fig. 3d). Furthermore, FAF1-mediated
inhibition of TbRII expression was partially rescued by N2,
N4-dibenzylquinazoline-2,4-diamine, an inhibitor of the ATPase
activity of VCP (Supplementary Fig. 3b).
VCP–UFD1–NPL4 as well as the E3 ligases bTRCP and
CULLIN1 were found to associate with TbRII in control cells but
not in FAF1-depleted cells (Fig. 3e). The loss of FAF1 had no
effect on the VCP–UFD1–NPL4 complex formation but led to a
reduced association between VCP-TbRII and VCP-bTRCP
(Fig. 3f). These results indicated that FAF1 recruits bTRCP to
the VCP complex and subsequently recruits VCP/bTRCP to
TbRII. This finding might be relevant for cell surface TbRII,
because we observed that FAF1 induced an increase in the levels
of both VCP–UFD1–NPL4 and bTRCP in the membrane fraction
(Supplementary Fig. 3c). To validate this hypothesis, we pulled
down biotin-labelled cell surface proteins and found that
FAF1-WT but not the UBX-deleted mutant increased plasma
membrane-associated VCP–UFD1–NPL4/bTRCP/CULLIN1 and
reduced the level of TbRII at the cell surface (Fig. 3g). In the
same assay, FAF1 depletion reduced cell surface-bound
VCP–UFD1–NPL4/bTRCP/CULLIN1 and increased the amount
of TbRII at the plasma membrane (Fig. 3h).
bTRCP is a F-box protein23. SGT1A, a homolog of S-phase
kinase-associated protein 1 (Skp1), was also identified as a
FAF1-binding partner (Fig. 3a; Supplementary Data 2). Thus,
FAF1 actually pulled down a SKP1-cullin1-F-box protein E3
ligase complex in which the substrate-recognition subunit bTRCP
plays an essential role24,25. In the ubiquitylation assay, FAF1
promoted TbRII polyubiquitylation, an effect that was inhibited
upon bTRCP depletion (Fig. 3i). Depletion of FAF1 together with
bTRCP therefore greatly decreased TbRII polyubiquitylation
(Fig. 3j). These results indicate that TbRII polyubiquitylation
is primarily accomplished by the FAF1/bTRCP complex.
Furthermore, ectopic expression of VCP also promoted
TbRII polyubiquitylation and TbRII turnover on the cell
surface—effects that were dependent on endogenous FAF1
expression (Fig. 3k). In summary, TbRII is primarily targeted
for polyubiquitylation and turnover in the lysosome by the VCP
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Figure 2 | FAF1 promotes TbRII turnover at the cell surface. (a) The immunoblot (IB) of cell lysate derived from HEK293T cells stably expressing
TbRII-HA and depleted of FAF1 that were treated with CHX (20 mgml 1) at the indicated time points. The amount of protein after CHX treatment was
expressed as a percentage of that present before treatment (time 0), and is shown in the right panel. The results are shown as the mean±s.d. of three
independent sets of experiments. (b) [35S]-methionine labelling and pulse-chase analysis of TbRII in control and MDA-MB-231 cells stably overexpressing
empty vector ( ), Myc-FAF1 wt or FAF1mUBX (UBX domain-deleted mutants). The amount of labeled protein precipitated after the chase was expressed
as the percentage of that at the beginning of the chase (time 0) and is shown in the right panel. The results are given as the mean±s.d. of three
independent sets of experiments. (c,d) IB of biotinylated cell surface TbRII in MDA-MB-231 cells stably overexpressing FAF1 wt/FAF1 UBX-deleted mutant
(mUBX) (c) or stably depleted of endogenous FAF1 by two independent shRNA (shFAF1 #1 and shFAF1 #2) (d) and treated with TGF-b (5 ngml 1) at the
indicated time points. Quantification of the band intensities is shown in the right panel. Band intensity was normalized to the t¼0 controls. The results are
presented as the mean±s.d. of three independent sets of experiments.
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FAF1 correlates with good prognosis in breast cancer patients.
Epithelial-like breast cancer cells can undergo epithelial-to-
mesenchymal transition (EMT), upon which they become more
migratory, invasive and metastatic26–28. The upregulation of
mesenchymal markers N-cadherin, fibronectin, smooth muscle
actin and vimentin, and the downregulation of epithelial marker
E-cadherin are typical characteristics of EMT. Gene set
enrichment analysis (GSEA) of the NKI breast cancer patients
data set29 demonstrated that gene signatures representing a good
prognosis or less invasiveness of the tumour were significantly
enriched in patients with higher levels of FAF1 expression
(n¼ 103) compared to those with lower expression of this gene
(n¼ 104), strongly suggesting that FAF1 correlates with a good
prognosis (Fig. 4a).
Using immunofluorescence, we found that FAF1-expressing
cells exhibited an epithelial-like phenotype similar to those
of control cells and cells treated with the TbRI kinase inhibitor
SB431542, whereas FAF1-depleted cells exhibited mesenchymal-
like characteristics. The latter phenotype was partially inhibited
by SB431542 (Supplementary Fig. 4a). Upon ectopic FAF1
expression, the changes in EMT marker expression induced by
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FAF1 18,935.37 55 64.8
VCP 14604.47 60 75.2
NPL4 1,851.23 30 44.6
VAPB 1,411.79 14 61.7
VAPA 1,061.75 15 56.1
UFD1 664.88 20 54.7
Ubiquitin 466.67 9 72.1
UBXD1 421.29 15 42.2
BTRCP 415.63 14 31.5
CULLIN1 197.25 16 23.2
p47 103.06 10 31.6
CULLN3 59.81 3 4.6
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Figure 3 | FAF1 recruits VCP/bTRCP to target TbRII for polyubiquitination. (a) Mass spectrometry studies of anti-Flag-FAF1 immunoprecipitants
revealed FAF1-binding partners. (b) FAF1 bound to VCP at a ratio close to 1:1. (c) The CAGA12-Luc SMAD-dependent transcriptional response of HEK293T
cells expressing VCP or VCP shRNA (#1 and #2) and treated with TGF-b (2.5 ngml 1) overnight is shown. The data are presented as the mean±s.d.
of three independent sets of experiments. (d) Immunofluorescence and 4, 6-diamidino-2-phenylindole (DAPI) staining of HeLa cells transfected with
TbRII-HA or TbRII-HA with V5-VCP plasmids. Scale bar, 10mm. (e,f) HEK293T cells were transfected with TbRII-Flag (e) or Flag-VCP (f) and with FAF1
depletion or not, as indicated. Cells were collected for immunoprecipitation (IP) and immunoblot (IB) analysis; 5% of the total cell lysate was loaded as an
input. (g,h) MDA-MB-231 cells expressing Myc-FAF1 wt/UBX-deletion mutant (mUBX) (g) or infected with FAF1 shRNA as indicated (h) were harvested
for biotinylation and immunoblot (IB) analysis. Co., control non-targeting shRNA. (i) HA-Ub stably expressing HEK293Tcells were transfected with TbRII-
Flag along with Myc-FAF1 and were infected with control (Co.sh) or bTRCP shRNA lentivirus as indicated. The cells were then collected for IP and IB
analysis. (j) HA-Ub stably expressing HEK293Tcells were transfected with TbRII-Flag and infected with bTRCP1/2 shRNA and/or FAF1 shRNA lentivirus as
indicated. Cells were then collected for IP and IB analysis. (k) HA-Ub stably expressed HEK293Tcells were transfected with TbRII-Flag and VCP, and were
infected with FAF1 shRNA lentivirus as indicated. Cells were then collected for IP and IB analysis. (l) Working model of how FAF1 mediates TbRII
polyubiquitylation and turnover via lysosomal mediated degradation.
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Ranked gene list in FAF1-low versus FAF1-high patients
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Figure 4 | FAF1 inhibits bone metastasis in transplantable mouse model of metastasis and correlates with good prognosis in breast cancer patients.
(a) Pre-ranked gene set enrichment analysis (GSEA) in FAF1-high versus FAF1-low patients. The consensus signature of the genes correlated with good
prognosis (upper panel) or lower invasiveness (lower panel) was enriched in FAF1-high compared with FAF1-low patients. (b) Immunoblot (IB) of control
and MCF10A-RAS cells stably expressing FAF1 or depleted of endogenous FAF1 (shFAF1) and treated with TGF-b (5 ngml 1) and SB431542 (10 mM) as
indicated for 48 h. Epithelial-to-mesenchymal transition (EMT) marker proteins were analysed as indicated. (c) Heat map of TGF-b target and EMT-related
genes in control or MCF10A-RAS cells stably expressing FAF1 or depleted of FAF1 (#1 and #2) and treated with or without TGF-b (1 ngml 1) for 8 h.
(d) Consensus signature of genes significantly and negatively correlated with breast cancer metastasis are enriched in FAF1-high versus FAF1-low patients,
as shown by pre-ranked GSEA. (e) Consensus signature of genes significantly and positively correlated with breast cancer metastasis (left panel),
especially bone metastasis (right panel), are enriched in FAF1-low versus FAF1-high patients, as shown by GSEA (right panel). (f) Bioluminescent imaging
(BLI) of three representative mice from each group at week 6 following injection with control or MDA-MB-231 cells stably expressing FAF1. Both ventral and
dorsal images are shown (upper panel). The BLI signal of every mouse (lower left panel) and the percentage of bone metastasis-free mice (lower right
panel) in each experimental group were followed over time. (g) The BLI of three representative mice from each group at week 6 following injection with
control or MDA-MB-231 cells stably depleted of FAF1 and pretreated with or without SB431542 (SB, 10mM) overnight. Both ventral and dorsal images are
shown (left panel). The BLI signal of every mouse (right upper panel) and the percentage of bone metastasis-free mice (right lower panel) in each
experimental group are shown over time. Data are presented as the mean±s.d.
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effect (Fig. 4b). To evaluate whether FAF1 regulates global
EMT-related changes, we performed gene expression profiling of
RAS-transformed MCF10A cells. PCR array analyses indicated
that the loss of FAF1 led to several molecular features of EMT,
including the upregulation of key transcriptional inducers such as
Twist1, Twist2, Snail1, Snail2, Snail3, Zeb1 and Zeb2. Importantly,
all of these genes were suppressed by an increase of FAF1 either
in the basal or TGF-b-induced level (Fig. 4c), indicating that
FAF1 could promote mesenchymal-to-epithelial transition. In
line with this finding, FAF1 attenuated TGF-b-induced migration
in two-dimensional transwell assays (Supplementary Fig. 4b) as
well as invasion in three-dimensional spheroid-collagen culture
systems (Supplementary Fig. 4c). In addition, knockdown of
endogenous FAF1 promoted breast cancer migration and
invasion (Supplementary Fig. 4b,d). Moreover, GSEA analysis
showed that genes correlating with decreased metastasis were
significantly enriched in FAF1-high patients (Fig. 4d), whereas
gene signatures linked to increased metastasis, especially in the
bone, were significantly enriched in FAF1-low patients (Fig. 4e).
We therefore directly investigated whether FAF1 suppresses bone
metastasis in a transplant mouse model.
We used the highly bone metastatic subline MDA-MB-231 to
evaluate the effect of FAF1 on metastasis30–32. Mice that had been
intracardially injected with control MDA-MB-231 cells began to
develop detectable bone metastases after 35 days, and the number
of metastatic nodules and the area covered by them expanded in
the following 2 weeks. Mice injected with FAF1-expressing cells
developed fewer bone metastases and had significantly longer
bone metastases-free survival periods (Fig. 4f). Furthermore, the
intracardial injection of cells expressing FAF1 short hairpin RNA
(shRNA) revealed potentiated bone colonization of circulating
MDA-MB-231 cells, which was partially blocked by pretreatment
of the cells with SB431542 (Fig. 4g). This finding confirms that
FAF1 inhibits breast cancer bone metastasis, at least in part, via
the suppression of TGF-b receptor signalling.
FAF1 depletion promotes lung metastasis in the MMTV-PyMT
mouse model. To determine the in vivo physiological functions
of FAF1, we generated FAF1-knockout mice by utilizing gene-
targeted ES cells in which exon 3 of the FAF1 gene had been
replaced with the neomycin-resistance gene to generate a frame
shift in the remaining FAF1 sequence (Fig. 5a; Supplementary
Fig. 5). FAF1 protein expression was greatly reduced in FAF1
heterozygous embryos and was absent in FAF1 homozygous
embryos (Fig. 5b), confirming gene knockout. FAF1 / female
mice were viable and fertile and displayed no obvious abnorm-
alities when monitored for up to 1 year. In FAF1þ / and
FAF1 / mouse embryonic fibroblast cells, we observed
stabilized cell surface localization of TbRII, which led to a
more sensitive TGF-b response as indicated by increased
TGF-b-induced phosphorylation of both SMAD2 and AKT
(Fig. 5c). The expression of downstream TGF-b target genes, such
as plasminogen activator inhibitor 1 (PAI1), interleukin 11 (IL11)
and N-Cadherin (CDH2), were also elevated in FAF1þ / and
FAF1 / mouse embryonic fibroblasts (Fig. 5d).
To complement our xenograft metastasis models, we examined
the effects of FAF1 on metastasis using the well-established
MMTV-PyMT transgenic mouse model. These mice develop
luminal adenocarcinoma with a high incidence of lung metastasis,
which relies on AKT activity33,34. Similar to the results obtained
from the xenograft models, we observed that FAF1 / /PyMT
and FAF1þ / /PyMT mice exhibited an increase in the incidence
of lung metastasis (Fig. 5e), as well as a significant increase in the
number of lung metastasis nodules (Fig. 5f) and greater lung
lesion surface area (Fig. 5g,h) compared with their FAF1þ /þ /
PyMT counterparts. Furthermore, the level of TbRII expression
was strongly increased in FAF1 / /PyMT lesions compared
with FAF1þ /þ /PyMT metastasis lesions (Fig. 5h). Finally, these
results were confirmed by independent experiments in which
FAF1-overexpressing primary tumour cells derived from MMTV-
PyMT transgenic mice (Fig. 5i) exhibited a significant decrease in
lung metastasis without detectable changes in primary tumour
growth following mammary fat pad injection in Friend Virus B
(FVB) mice (Fig. 5j–m). Overall, our data from transgenic mice
experiments complement our findings from cell line models and
clinical breast cancer samples, strongly supporting the role of
FAF1 as a metastasis-suppressing gene via the direct targeting of
TbRII.
AKT phosphorylates FAF1 to inhibit its membrane localiza-
tion. In FAF1-expressing epithelial-like cells, the initiation of an
oncogenic TGF-b signal requires the dissociation of FAF1 from
TbRII. We next investigated how this process is achieved. In our
mass spectrometry analysis, we found that FAF1 was phos-
phorylated on residues Ser 270, Ser 320 and Ser 582
(Supplementary Fig. 6a; Supplementary Table 2). Ser 582 is an
AKT consensus RxRxxS(T) phosphorylation motif conserved in
FAF1 orthologs (Fig. 6a,b); the other conserved residue, Ser 426,
was not phosphorylated (Supplementary Fig. 6b). FAF1 was
associated with AKT in vitro and in vivo (Supplementary
Fig. 6c,d). We used a phospho-specific antibody that recognizes
the optimal AKT phosphorylation consensus motif and found
that endogenous FAF1 was indeed phosphorylated by AKT;
this phosphorylation was elevated by an activated allele of AKT
(Myr-AKT1) and was blocked by LY294002, a selective inhibitor
of PI3K (Fig. 6c). Using in vitro and in vivo assays, we found that
AKT phosphorylated FAF1 (Fig. 6d; Supplementary Fig. 6e).
Phosphorylation was not detected for the FAF1 S582A mutant
but was present in FAF1 protein with other sites mutated
(Fig. 6d). The reactivity of FAF1 with the p-AKT substrate
antibody was reversed when the cell lysates were incubated with
lambda phosphatase (Supplementary Fig. 6f). These data strongly
suggest that AKT specifically phosphorylates FAF1 at Ser 582.
Under physiological conditions, both insulin-like growth factor
(IGF)-1 and TGF-b-induced phosphorylation of endogenous
FAF1 were detected by the AKT substrate antibody and were
abolished when the cells were treated with LY294002 (Fig. 6e),
indicating that FAF1 is regulated by various cytokines and
oncogenic stimuli that activate AKT.
The phosphorylation of certain AKT substrates controls their
subcellular localization35. Cell fractionation analysis showed
that activated Myr-AKT inhibits the membrane localization of
FAF1-WT, but not of the phospho-resistant FAF1-S582A
(Fig. 6f). Compared with FAF1-WT, the basal level of FAF1-
S582A in the membrane fraction was increased, whereas the
phospho-mimetic FAF1-S582D was undetectable (Supplementary
Fig. 7a). Upon LY294002 treatment or the expression of activated
AKT, endogenous FAF1 showed increased or reduced
localization, respectively, at the membrane, leaving the FAF1
level unchanged in both the cytoplasmic and nuclear fractions
(Fig. 6g). Similarly, TGF-b reduced the membrane association of
FAF1, which was rescued by the selective inhibition of either
PI3K (LY294002 or BKM120) or AKT (GDC0068 or MK2206),
suggesting that the effect was dependent on PI3K/AKT activity
(Fig. 6h; Supplementary Fig. 7b). Therefore, Ser 582 phosphory-
lation by AKT inhibited the membrane localization of FAF1. We
further hypothesized that this phosphorylation might also affect
the capacity of FAF1 to recruit the VCP/E3 complex (Fig. 6i).
AKT phosphorylates FAF1 thus disrupts FAF1-VCP/bTRCP
complex. Ser 582 is located in the FAF1 UBX domain, a region
that is required for FAF1’s association with VCP and bTRCP18,20.
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This fact suggests that the binding of FAF1 to VCP might be
influenced by AKT. In Myr-AKT-expressing cells, FAF1 barely
bound to TbRII and inefficiently recruited VCP-UFD1-NPL4 or
bTRCP/CULLIN1 (Fig. 7a). To verify whether this finding is due
to Ser 582 phosphorylation, we compared interactions using
FAF1-WT/S582A/S582D constructs. FAF1-S582A showed a
higher binding affinity for TbRII, VCP-UFD1-NPL4 and
bTRCP/Cullin1, whereas FAF1-S582D exhibited decreased
interactions with these proteins (Fig. 7b). In line with this
finding, FAF1-S582A potentiated TbRII ubiquitylation more
efficiently (Fig. 7c). In cells expressing FAF1-WT/S582A/S582D
mutants, we isolated cell surface biotin-labelled proteins and
found that FAF1-S582A significantly increased VCP-UFD1-
NPL4 and bTRCP/Cullin1 in the cell membrane fraction,
thereby reducing the cell surface expression of TbRII (Fig. 7d).
This suggests that the negative effects of FAF1 on TbRII could be































































































































































































































































Figure 5 | Loss of Faf1 in mice results in the accumulation of TbRII and promotes lung metastasis in the MMTV-PyMT transgenic mouse model.
(a) Genotyping of the generated FAF1þ /þ , FAF1þ / and FAF1 / mouse lines. PCR analysis of genomic DNA obtained from the tails of E13.5
mouse embryos. The asterisk indicates a FAF1 knockout-specific band. (b) IB of FAF1 protein derived from mouse embryonic fibroblasts (MEFs) from E13.5
FAF1þ /þ , FAF1þ / and FAF1 / embryos. (c) FAF1þ /þ , FAF1þ / and FAF1 / primary MEFs from E13.5 embryos were treated with TGF-b
(5 ngml 1) for 45min and then collected for biotinylation and IB analysis for cell surface TbRII expression. Expression levels of (phosphorylated) SMAD2
and AKT are also shown by IB with indicated antibodies. (d) FAF1þ /þ , FAF1þ / and FAF1 / primary MEFs from E13.5 embryos were collected for
quantitative PCR with reverse transcription (qRT–PCR) analysis of TGF-b-targeted and invasion-related genes. Relative mRNA levels are shown as a
heat map. (e–g) The incidence of spontaneous lung metastasis (e), the number of lung metastasis lesions (f) and the average lung lesion surface area
(g) (arbitrary units based on pixel quantification from digital images, the data represented are shown as the mean±s.d.) from FAF1þ /þ/MMTV-PyMTþ
(n¼9), FAF1þ //MMTV-PyMTþ (n¼8) and FAF1 //MMTV-PyMTþ animals (n¼ 10). *Po0.05 by Mann–Whitney U-test in f and Student’s t-test
in g. (h) TbRII staining in lung lesions collected from FAF1þ /þ/MMTV-PyMTþ or FAF1 //MMTV-PyMTþ mice. Scale bars, 1mm and 20mm for lung
haematoxylin and eosin (H&E) and TbRII immunohistochemistry images, respectively. (i–m) Overexpression of FAF1 in MMTV-PyMT tumour cells inhibits
lung metastasis. (i) qRT–PCR analysis of FAF1 expression in control or FAF1-overexpressing MMTV-PyMT primary tumour cells. Experiments were
performed three times, each with qRT–PCR in technical duplicates. The data are presented as the mean±s.d. (j) Volumes of primary mammary fat pad
tumours; n¼6 per experimental group. P value computed by Mann–Whitney U-test. (k,l) The incidence of spontaneous lung metastasis (k) and the
number of lung metastasis lesions (l) in control and FAF1-overexpressing primary tumours; n¼6 per experimental group, **Po0.01 by Mann–Whitney
U-test in l. (m) Representative lung nodules from mice injected with control and FAF1-overexpressing MMTV-PyMT tumour cells. Black arrowheads
indicate lung metastasis nodules. Scale bar, 2mm.
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These data suggest that the initial activation of AKT
(for example, by oncogenic mutation or the activation of receptor
tyrosine kinases) dissociates FAF1 from TbRII. TbRII may in
turn lead to the further enhancement of SMAD and non-SMAD
AKT activation downstream of TbRII. This process is a self-
enforcing loop. If this mechanism indeed occurs during cancer
progression, PI3K/AKT activity should correlate with TbRII
levels in malignant cells. Indeed, blocking PI3K/AKT activity
enhanced TGF-b-induced and FAF1-dependent TbRII ubiquity-
lation (Fig. 7e). AKT inhibited TbRII polyubiquitylation induced
by FAF1-WT but had no effect in the case of FAF1-S582A
(Supplementary Fig. 7c). TbRII was reduced to a low level
by LY294002 in bone metastatic MDA-MB-231 cells,
which impaired SMAD phosphorylation by TGF-b (Fig. 7f;
Supplementary Fig. 7d). This process is apparently related to
FAF1 recruitment of VCP; first, LY294002-induced loss of
TbRII was rescued by N2, N4-dibenzylquinazoline-2,4-diamine,
a selective VCP inhibitor (Fig. 7f). Second, LY294002-induced
decrease of cell surface TbRII was not observed in FAF1-depleted
cells (Fig. 7g).
To directly implicate FAF1 and its regulation by
AKT-mediated phosphorylation in metastasis, we used a
doxycycline-regulated promoter to express FAF1 wt or the
phosphorylation-resistant S582A mutant in MDA-MB-231 cells
4 weeks after intracardial injection (Fig. 7h). The immediate
expression of FAF1 wt significantly delayed metastatic outgrowth,
whereas the expression of FAF1 S582A nearly abolished it
(Fig. 7h). This result suggests that the induction of FAF1
expression could inhibit metastasis, but FAF1 protein was
functionally suppressed by endogenous AKT kinase. In summary,
AKT antagonizes FAF1 to maintain TbRII stability in metastatic
(malignant) breast cancer cells (Fig. 7i).
The non-SMAD signals downstream of TbRII incorporates
AKT, leading to the positive amplification loop of AKT-TGF-b
signalling (Fig. 7i).
Loss of FAF1 correlates with gain of TbRII function in
patients. Our findings suggest that pre-activated AKT phos-
phorylates and therefore antagonizes FAF1, which subsequently
strengthens cell surface TbRII and results in the reinforced co-
activation of SMAD and non-SMAD signalling (for example,
AKT), which promote metastasis. To verify this model, we used
an orthotopic mouse model. Pre-treatment with epidermal
growth factor (EGF) at a low dose promoted the lung metastasis
of 4T1 cells without significantly altering primary tumour growth
under the nipple; this effect on metastasis was further promoted
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Figure 6 | AKT phosphorylates FAF1 at Ser 582 and inhibits its membrane localization. (a) Sequence alignment of the AKT phosphorylation site within
FAF1 orthologs from different species and the known AKT-phosphorylating proteins p27, p21 and Skp2. (b) AKT-phosphorylated FAF1 peptide identified by
mass spectrometry analysis. (c) Immunoblot (IB) of total cell lysate (TCL) and immunoprecipitants derived from HeLa cells transfected with Myr-HA-AKT
and treated with increasing doses of LY294002 (25 and 50mM) for 12 h as indicated. NS, non-specific antibody. (d) HEK293T cells were transfected with
Flag-FAF1 wt or S582A, T426A, S270A or S320A mutants along with Myr-HA-AKT expression plasmids as indicated. Cells were then collected for
immunoprecipitation (IP) and IB analysis. (e) IB analysis of TCL and anti-FAF1 immunoprecipitates derived from serum-starved HeLa cells treated with
IGF-1 (200ngml 1), TGF-b (5 ngml 1) and LY294002 (50mM) as indicated for 8 h. (f) HeLa cells stably overexpressing FAF1 wt or FAF1 S582A mutant
constructs were transfected with or without HA-Myr-AKT as indicated. Cells were then collected for membrane (Mem), cytoplasm (Cyto) and nuclear
(Nuc) extraction and IB analysis. (g) IB of Mem, Cyto and Nuc extraction derived from HeLa cells transfected with or without HA-Myr-Akt and treated with
LY294002 (50 mM for 12 h) as indicated. (h) HeLa cells were treated with TGF-b (5 ngml 1) and selective PI3K inhibitors LY294002 (50mM) or BKM120
(1mM) as indicated for 8 h. Cells were then collected for Mem, Cyto and Nuc extraction and IB analysis. (i) Hypothetical working model of AKT-mediated
FAF1 phosphorylation: phosphorylated FAF1 does not efficiently attach to the cell surface or associate with the VCP/E3 complex.
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To determine the clinical relevance and validity of our findings,
we examined the expression of TbRII, P-SMAD2 and P-AKT 473,
and their relationship with FAF1 in patient-derived tissue
samples. We performed immunohistochemistry analysis on
invasive breast carcinomas (110 cases), with tumour-adjacent
normal breast tissue samples (11 cases) as controls. TbRII,
P-SMAD2 and P-AKT 473 levels were significantly higher in
breast carcinomas, whereas the FAF1 level was significantly lower
in cancer tissues compared with normal breast tissues (Fig. 8c).
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observed a significant inverse correlation between high FAF1 level
and high levels of TbRII (Pearson w2¼ 38.03, P¼ 3.5E 08),
P-SMAD2 (Pearson w2¼ 7.85, P¼ 0.001) and P-AKT 473
(Pearson w2¼ 1.88, P¼ 0.05; Fig. 8d,e; Supplementary
Fig. 8a,b). As shown in Fig. 8d, representative staining of the
serial sections showed that the relative low FAF1 staining
correlates with high levels of TbRII, P-SMAD2 and P-AKT 473,
which were all found to be low in high FAF1 samples
(Supplementary Fig. 8a). As a control, we confirmed a significant
and positive correlation between TbRII and its downstream target
P-SMAD2 (Pearson w2¼ 27.44, P¼ 3.37E 06; Supplementary
Fig. 8c,e); more importantly, activation of AKT (P-AKT 473)
positively correlated with TbRII (Fig. 8f; Supplementary Fig. 8c),
confirming our finding that AKT activity supports TbRII
function and collaborates with TGF-b-induced pro-invasive and
pro-metastatic responses in advanced tumours. Our data also
highlight the frequent co-activation of AKT and SMAD in breast
cancer (Supplementary Fig. 8d,f), suggesting that AKT could
cooperate with SMAD to drive malignancy.
Discussion
TGF-b signalling is hyperactivated in advanced cancers36. We
found that TbRII protein levels are increased in metastasis, and
that TbRII levels determine metastasis severity, raising a novel
mechanism by which TGF-b signalling is activated. As the first
signalling molecule engaged by the TGF-b ligand, cell surface
TbRII is thought to be required for all TGF-b signalling
responses. As a low dose of TbRII is sufficient for cytostatic
SMAD activation, an increase in TbRII levels contributes to
cancer and drug resistance37, and TbRII expression in CAFs
supports cancer growth and survival38. Here we provide
important new insights into how cell surface TbRII is
dynamically regulated in stability and subcellular localization
through FAF1-mediated polyubiquitination. We generated FAF1-
knockout mice and found that cell membrane TbRII accumulates
in FAF1-deficient cells from mouse embryos, confirming that
FAF1 restrains TbRII function under physiological conditions.
Pathologically, we identified FAF1 as a strong suppressor of
TGF-b signalling and showed that it recruits the VCP/bTRCP
complex to promote turnover of cell surface TbRII, thereby
inhibiting tumorigenic TGF-b function in EMT, invasion and
metastasis. This was confirmed by multiple in vivo models of
metastasis, an MMTV-PyMT transgenic model of mammary
tumour progression and clinical breast cancer samples.
FAF1 is highly expressed in normal epithelial cells or
pre-malignant cells (such as MCF7 or MCF10A cells) but is
attenuated in the well-established mesenchymal-like MDA-MB-
231 cells; thus, it limits the amount of cell surface TbRII to
prevent excessive TGF-b responses. Our study revealed that
activated AKT and TGF-b cooperate to antagonize the inhibitory
effect of FAF1 on TGF-b signalling. When oncogenic AKT is
aberrantly activated in cells (for example, by oncogenic mutations
or excessive growth factors39), AKT can directly phosphorylate
FAF1 at Ser 582, which dissociates FAF1 from the cell surface and
disrupts its ability to complex with VCP/bTRCP, which is
required for the polyubiquitylation of TbRII. This process
apparently allows for the activation of both SMAD and
non-SMAD pathways. In this context, the tumour-suppressive
effects of the SMAD pathway are abrogated by AKT4; thus,
SMAD-dependent gene responses are advantageous for cancer
migration and invasion. The subverted TGF-b/SMAD signalling
pathway then actively drives tumour cell progression. Tumour
cells with this signature fail to execute TGF-b/SMAD-mediated
growth arrest; rather, they undergo EMT in which cells lose cell
polarity and cell–cell contacts, become more motile, and acquire
fibroblast-like properties. AKT has been shown to reduce SMAD3
function in Hep3B cells in which TGF-b induces an apoptotic
response7,8. However, SMAD3 levels are often reduced in
advanced human tumours, and low SMAD3 levels are sufficient
for tumour promotion40,41. Aberrant AKT over-activation may
therefore redirect TGF-b intracellular signalling, thereby
contributing to its switch from tumour suppressor to tumour
promoter. Thus, AKT-mediated inactivation of FAF1 protein
confirms the high level of cell surface TbRII, which in turn
further strengthens both SMAD and AKT (one of the non-SMAD
pathways) signals. Thus, a self-enforcing loop directing the
tumour-promotive TGF-b pathway is triggered by AKT through
the inactivation of FAF1, via which cancer cells are stimulated to
invade and metastasize.
FAF1 gene loss was observed to be significantly and inversely
correlated with TGF-b3 gene expression. In light of the FAF1
downregulation and the loss of epithelial differentiation that we
clearly observed in different breast cancer models, we found the
clinical relevance of FAF1 in the percentage of distant metastasis-
free survival of breast cancer patients where the cutoff by FAF1
expression correlates with prognosis (Fig. 1j). EMT is only clearly
detectable in low frequent breast carcinosarcomas such as the
molecular subtype of claudin-low breast cancers. We found that
the claudin-low clinical samples have reduced expression of
FAF1, further supporting our analysis. Importantly, FAF1 gene
loss has been reported in many types of human cancers,
suggesting that the tumour-suppressive role of FAF1 is not
limited to breast cancer. Moreover, both TbRII and P-SMAD2
levels correlated inversely with the FAF1 level in our breast cancer
tissue microarray analysis, further corroborating that FAF1 plays
an essential role in controlling TbRII and TGF-b signals. In vivo
cancer models using cell lines or transgenic mice consistently
showed that loss of FAF1 expression is closely associated with
breast cancer metastasis. Either loss of FAF1 or disassembly of the
Figure 7 | AKT-mediated phosphorylation of FAF1 at Ser 582 functionally disrupts the FAF1-VCP/E3 complex and dismisses FAF1 from targeting cell
surface TbRII. (a,b) Immunoblot (IB) of total cell lysate (TCL) and immunoprecipitants derived from HEK293T cells transfected with Flag-FAF1 and
Myr-HA-AKT (a) or Flag-FAF1 wt/S582A/S582D expression plasmids (b) as indicated. *Indicates a non-specific band. (c) IB of TCL and
immunoprecipitants derived from Myc-Ub stably expressed HEK293T cells transfected with TbRII-HA and Flag-FAF1 wt/SA/SD expression plasmids as
indicated. (d) IB of TCL and biotinylated cell surface TbRII in MDA-MB-231 cells infected with Flag-FAF1 wt/S582A/S582D as indicated. (e) IB of TCL and
immunoprecipitants derived from Myc-Ub stably expressed HEK293T cells transfected with TbRII and shFAF1 plasmids and treated with or without LY
294002 (LY, 50mM for 6 h) and TGF-b (5 ngml 1) at the indicated time points. (f) IB of total TbRII in bone metastatic MDA-MB-231 cells treated with
dimethylsulphoxide (DMSO) or N2, N4-dibenzylquinazoline-2,4-diamine (DBeQ; 10mM) and LY294002 (50 mM) at the indicated time points. (g) IB of
TCL and biotinylated cell surface TbRII in bone metastatic MDA-MB-231 cells infected with control (Co.sh) or shFAF1 lentivirus and treated with LY294002
(50mM) at the indicated time points. (h) MDA-MB-231 cells expressing control vector (Co.vector) or DOX-inducible FAF1 wt/FAF S582A were injected
intracardially into mice. DOX was administered 28 days after the inoculation of the cells (as indicated). Metastasis was measured by BLI. Normalized
photon flux for the indicated time is presented; error bars, mean±s.e. P values; Student’s t-test (left panel). Representative images (right panel). (i) In our
working model, AKT phosphorylates FAF1 to disassociate the membrane FAF1–VCP/E3 complex, thereby stabilizing cell surface TbRII for oncogenic
invasion or metastasis (in which AKT activation has already blunted cytostatic TGF-b/SMAD to support oncogenic growth).
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Figure 8 | Loss of FAF1 correlates with increased TbRII as well as downstream p-SMAD2 and p-AKTexpression in patients. (a) Bioluminescent imaging
(BLI) of representative mice from each group at week 3 following injection with empty vector (PLKO.1) or 4T1 breast cancer cells stably depleted of FAF1
and pre-treated with or without EGF (5 ngml 1) for 8 h. Ventral images of the mice are shown (left panel). The BLI signal from primary tumours obtained
from every mouse in each experimental group is shown. NS, not significant (right panel). (b) BLI of representative metastatic nodules in the lung from each
experimental group is shown (left panel). Lung metastasis BLI signal for every mouse in each experimental group was analysed and is shown in the right
panel (right panel). Data are presented as the mean±s.d. (c–f) Immunohistochemistry analysis of FAF1, TbRII, p-SMAD2 and P-AKT 473 in breast cancer
tissue microarrays; expression of FAF1 and TbRII, P-SMAD2 and P-AKT 473 in normal (n¼ 11) and breast cancer (n¼ 110) tissues. The data are the
mean±s.e.m. P values obtained using Student’s t-tests are indicated (c). Representative images of each antibody staining are shown. Left panel: objective,
 5; right panel: objective,  25 (d). Percentage of specimens displaying low or high FAF1 expression compared with the expression levels of TbRII,
P-SMAD2 and P-AKT (e). Scatterplot showing the positive correlation between TbRII and P-AKT 473 expression in patients. Pearson’s coefficient tests
were performed to assess significance (f).
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FAF1/VCP/bTRCP complex via AKT phosphorylation can lead
to increased breast cancer metastatic potential. We evaluated in
the breast cancer tissue microarray specimens and found the
status of AKT activation (p-AKT 473 staining) and FAF1
expression (FAF1 staining) were not correlated, suggesting that
these two events might be independent of each other.
In metastatic breast cancer cells, blocking PI3K/AKT activity
reverses TbRII expression to a very low level (Fig. 7f,g;
Supplementary Fig. 7d), demonstrating that TbRII-mediated
oncogenic TGF-b signalling is supported by AKT activity.
Therapeutic targeting of PI3K/AKT holds significant promise as
a treatment for cancer patients42. Our results suggest that targeted
therapy of the PI3K/AKT pathway may already, in part, target
TGF-b signalling. Moreover, combined therapeutics against
PI3K/AKT and TbRII might serve as an efficient method for
advanced breast cancer patients in the future4.
In human patients, 70% of breast cancers are oestrogen
receptor a (ER) positive and are thus treated with endocrine
therapies. However, 25% of these cancers eventually develop
endocrine resistance due to ESR1 gain-of-function mutations,
with ligand-independent ER activity driving metastasis43–45. In
an analysis of 4500 breast cancer patients, ESR1 apparently
correlated with the loss of FAF1. It is therefore likely that ESR1
correlates with a gain of TbRII function. Thus, endocrine
resistance by ESR1 could be the result of oncogenic TGF-b
activation. Although this hypothesis awaits further investigation,
it raises the possibility that combined treatment with a TGF-b
antagonist could counteract the development of tolerance to
endocrine therapy in ER-positive breast cancer patients.
In closing, our study proposes models of TbRII control and
TGF-b functional switch triggered by activation of AKT. It will be
interesting to see in the future whether the mechanisms we have
unravelled will extend to other cancers. If so, these hitherto
underappreciated roles of TGF-b in malignancy and drug
resistance could serve as a foundation for improving therapeutics
against devastating cancers.
Methods
Animal studies. All mouse experiments were approved by and performed
following the guidelines of the Institutional Animal Care and Use Committee at
Zhejiang University.
Nude mice and cell culture. Nude mice were purchased from the animal
husbandry centre of the Shanghai Institute of Cell Biology, Academia Sinica,
Shanghai, China. HEK293T cells, HeLa cervical cancer cells, MCF7, MDA-MB-231,
MDA-MB-435 breast cancer cells and A549 lung cancer cells from Leiden Uni-
versity Medical Center46,47 were cultured in DMEM supplemented with 10% fetal
bovine serum and 100Uml 1 penicillin–streptomycin. MCF10A (M1), MCF10A-
RAS (M2), M3 and M4 cells were cultured in DMEM/F12 supplemented with 5%
horse serum, 20 ngml 1 EGF, 0.5 mgml 1 hydrocortisone, 100 ngml 1 cholera
toxin and 100Uml 1 penicillin–streptomycin.
Generation of Faf1 / mice. Faf1flox/þ mice (C57BL/6J) were generated by
standard homologous recombination at Shanghai Biomodel Organism, Shanghai,
China. In these mice, Faf1 exon 3 was flanked by loxP sequences. Faf1flox/þ mice
were then mated to EIIa-Cre transgenic mice (FVB/N; Jackson Laboratory), in
which the adenovirus EIIa promoter directs the expression of Cre enzyme in early
mouse embryos (two- to eight-cell stage) to achieve homologous recombination
between LoxP sites, thereby triggering the deletion of exon 3 in all cells of the
developing animal, including the germ cells that transmit the genetic alteration to
progeny. Deletion of exon 3 results in loss of the signal peptide and disrupts its
ORF, leading to the loss of Faf1 expression. The first generation of EIIa-Cre;
Faf1flox/þ mice might be chimeric due to the mosaic activity of Cre recombinase.
Therefore, chimeric offspring were backcrossed with C57BL/6J to generate
Faf1þ / mice, which were then intercrossed for the production of Faf1-deficient
(Faf1 / ) mice. Mouse genotyping was performed using genomic DNA isolated
from mouse tails by PCR with the following primers: 50-CAGCCCACAACT
CACCTTTT-30 (faf1-KO-P1); 50-AATTGAAGGCCAGACGTAGC-30 (faf1-KO-
P3-W686); 50-CTGAGCCCAGAAAGCGAAGGA-30 (Neo-R). A 1,086-bp and
B686-bp fragment were produced for the WT and null alleles, respectively.
Mouse metastasis assay. MDA-MB-231-Luc and A549-Luc cells32 were
used to stably overexpress or were depleted of target genes by lentivirus
infection and puromycin selection for 3 days. A single-cell suspension of these cells
(1 105/100 ml of PBS) was inoculated into the left heart ventricle (n45) according
to the method described by Arguello et al.48. The development of metastases was
monitored weekly by bioluminescent reporter imaging. After 6 weeks (or according
to the description in the figure legend), the mice were killed, and the metastasis
nodules were dissected. For the induced model, doxycycline was administered to
mice at indicated time point after injection of the cancer cells, through the diet
(625mg kg 1 of food) as well as by intraperitoneal injection (25mg kg 1 of body
weight; three times a week). For the MMTV-PyMT models, FAF1 KO mice were
backcrossed to FVB background for more than six generations before breeding
with MMTV-PyMT transgenic mice (Jackson Laboratory) in FVB background.
For spontaneous tumorigenesis and metastasis studies, female mice carrying the
specific oncogenes were examined weekly for mammary tumours. Tumours were
considered established when they became palpable for 2 consecutive weeks, and
tumours were measured by calipers for calculation of tumour volumes
(p lengthwidth2/6). Lung nodules were counted directly after fixation or after
sectioning and staining of the lungs. For orthotopic primary tumour formation,
female FVB (for PyMT tumour cells experiments) mice at 6 weeks old were
anaesthetized and a small incision was made to reveal the mammary gland.
MMTV-PyMT tumour cells (2.5 104) resuspended in 10 ml PBS were injected
directly into the mammary fat pad. The primary tumour growth was monitored
weekly by measurement of the tumour size. Experimental metastasis to the lungs
was induced by injecting 0.2 106 cells in 100 ml of PBS in the tail vein of female
athymic nude mice. Mouse nipple implantation of 4T1 cells was based on a
previously published method49. Female BALB/c mice were anaesthetized and used
for this assay. A total of 1 105 4T1-Luc cells were injected through the nipple area
into the mammary fat pad. At 21 days after injection, luciferin was injected and the
primary tumours were analysed, then the mice were killed and analysed for
acquisition of secondary tumour(s). All primary/metastatic tumours were detected
by bioluminescent imaging with the IVIS 100 (Caliper Life Sciences, Hopkinton,
MA, USA). The bioluminescent imaging signal intensity was quantified as the sum
of photons within a region of interest given as the total flux (photons per second).
GSEA. We used GSEA v2.0 to perform GSEA on various functional and/or
characteristic gene signatures. Gene sets were obtained from the MSigDB database
v3.0 (September 2010 release). Statistical significance was assessed by comparing
the enrichment score to enrichment results generated from 1,000 random
permutations of the gene set to obtain P values (nominal P value). Data from
NKI 295, a well-annotated human breast cancer database, were analysed for the
enriched gene signature, and FAF1-high (FAF1Z0.28, n¼ 103) versus FAF1-low
(FAF1r 0.34, n¼ 104) samples were compared.
Plasmids and reagents. FAF1 and related expression constructs were cloned and
verified by DNA sequencing. FAF1 wt and FAF1 UBX domain-deleted mutant
fragments were subcloned into the pLv-bc-puro lentivirus construct. FAF1 S582A
and other mutants were generated by site-directed mutagenesis and confirmed by
DNA sequencing. Myr-AKT1 constructs were kindly provided by P. Coffer
(University Medical Center Utrecht, The Netherlands). The reagents used were
IGF-1 (R&D 291-G1), LY294002 (Cell Signalling), MG132 (Selleck, catalog no.
S2619), CHX (Sigma, C104450), SB431542 (Millipore, 616461) and l-phosphatase
(Biolabs). BKM120, MK2206 and GDC0068 were purchased from Selleck. The
recombinant proteins used were human active AKT1 protein (R&D, 1775-KS),
TbRII-ICD (Sino Biological Inc., 10358) and TGF-b (Sino Biological Inc., 10804).
Immunoprecipitation and immunoblotting. Cells were lysed with 1ml of lysis
buffer (20mM Tris-HCl pH 7.4, 2mM EDTA, 25mM NaF and 1% Triton X-100)
containing protease inhibitors (Sigma) for 10min at 4 C. After centrifugation at
12 103g for 15min, the protein concentrations were measured, and equal
amounts of lysate were used for immunoprecipitation. Immunoprecipitation was
performed with different antibodies and protein A-Sepharose (GE Healthcare
Bio-Sciences AB) for 3 h at 4 C. Thereafter, the precipitants were washed three
times with washing buffer (50mM Tris-HCl pH 8.0, 150mM NaCl, 1% Nonidet
P-40, 0.5% sodium deoxycholate and 0.1% SDS), and the immune complexes were
eluted with sample buffer containing 1% SDS for 5min at 95 C. The immuno-
precipitated proteins were then separated by SDS–polyacrylamide gel electro-
phoresis (SDS–PAGE). Western blotting was performed with specific antibodies
and secondary anti-mouse or anti-rabbit antibodies conjugated to horseradish
peroxidase (Amersham Biosciences). Visualization was achieved with chemilumi-
nescence. For proteins that migrated close to the IgG heavy chain, protein
A-horseradish peroxidase was used. Biotinylation analysis of cell surface receptors
was performed as previously described46,47, the details were shown below. The cells
were biotinylated for 40min at 4 C and then incubated at 37 C for the indicated
times. The biotinylated cell surface receptors were precipitated with streptavidin
beads and analysed by immunoblotting. The antibodies used for immunopreci-
pitation, immunoblotting and immunofluorescence were as follows: AKT at 1:5,000
(IB) and 1:250 (IP; no. 2938, Cell Signalling); phospho-AKT substrate (RXRXXS*-
T*) at 1:1,000 (IB; no. 10001, Cell Signalling); phospho-AKT (Ser 473) at 1:1,000
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(IB; no. 9271, Cell Signalling); TbRII at 1:1,000 (IB) and 1:50 (IP; L-21, Santa
Cruz); N-cadherin at 1:50,000 (IB; 610920, BD); tubulin at 1:1,000 (IB; no. 2146,
Cell Signalling); SMAD4 at 1:1,000 (IB; B8, Santa Cruz); SMAD2-3 at 1:2,500 (IB)
and 1:500 (IP; 610842 BD); phospho-SMAD2 at 1:5,000 (IB; no. 3101, Cell
Signalling); p38 at 1:3,000 (IB; no. 535, Santa Cruz); p-p38 at 1:2,000 (IB; no. 4511,
Cell Signalling); Ub at 1:1,000 (IB; P4D1 Santa Cruz); fibronectin at 1:1,000 (IB;
Sigma); SMA (Sigma); vimentin at 1:1,000 (IB; no. 5741 Cell Signalling);
E-cadherin at 1:10,000 (IB; BD 610181); b-actin at 1:10,000 (IB; A5441, Sigma);
c-Myc at 1:1,000 (IB; a-14, sc-789, Santa Cruz Biotechnology); HA at 1:1,000 (IB;
Y-11, sc-805, Santa Cruz Biotechnology); HA at 1:10,000 (IB; 12CA5, home-made);
Flag at 1:10,000 (IB; M2, Sigma); FAF1 (Bethyl Laboratories); VCP at 1:2,000 (IB;
no. 2648, Cell Signalling); Ufd1 at 1:1,000 (IB; no. 13789, Cell Signalling); Npl4 (IB;
no. 13489, Cell Signalling); Cul1 at 1:1,000 (IB; no.4995 Cell Signalling); and
bTRCP at 1:1,000 (IB; no. 4394, Cell Signalling). All the uncropped scans of the
western blots are shown in Supplementary Fig. 9.
Lentiviral transduction and the generation of stable cell lines. Lentiviruses
were produced by transfecting HEK293T cells with shRNA-targeting plasmids and
the helper plasmids pCMV-VSVG, pMDLg-RRE (gag/pol) and pRSV-REV. The
cell supernatants were collected 48 h after transfection and were either used to
infect cells or stored at  80 C. To obtain stable cell lines, cells were infected at
low confluence (20%) for 24 h with lentiviral supernatants diluted 1:1 in normal
culture medium in the presence of 5 ngml 1 of polybrene (Sigma). At 48 h after
infection, the cells were placed under puromycin selection for 1 week and then
passaged before use. Puromycin was used at 1 mgml 1 to maintain MDA-MB-231,
MCF10A and HaCaT cells. Lentiviral shRNAs were obtained from Sigma
(MISSION shRNA). Typically, five shRNAs were identified and tested, and the
two most effective shRNAs were used for the experiment. We used the following
shRNAs:
TRCN000000424 (1#) and TRCN000000424 (#2) for human FAF1 knockdown;
TRCN0000004 250 (1#) and TRCN0000004 252 (#2) for human VCP knockdown;
TRCN0000006541þTRCN0000315200 mixture for Human bTRCP
knockdown; TRCN000039793þTRCN000039797þTRCN000010162
þTRCN0000010174 mixture for Human AKT1 knockdown; and
TRCN0000191433 for mouse FAF1 knockdown.
Transcription reporter assay. HEK293T cells were seeded in 24-well plates and
transfected with the indicated plasmids using calcium phosphate. At 24 h after
transfection, the cells were treated with TGF-b overnight or left untreated and then
collected. Luciferase activity was measured with a PerkinElmer luminometer.
The internal transfection control Renilla expression plasmid (10 ng) was used to
normalize luciferase activity. Each experiment was performed in triplicate, and the
data represent the mean±s.d. of three independent experiments.
Quantitative real-time PCR. Total RNA samples were prepared using a
NucleoSpin RNA II kit (Biospin). A total of 1 mg of RNA was reverse-transcribed
using the RevertAid First Strand cDNA Synthesis kit (Fermentas). Real-time
PCR was conducted with SYBR Green (Applied Bioscience) using a StepOne Plus
real-time PCR system (Applied Bioscience). Target gene expression values were
normalized to 18S RNA levels. All primers used in quantitative PCR with reverse
transcription are listed in Supplementary Table 3.
Ubiquitination assay. Cells were washed with PBS and lysed in two pellet volumes
of RIPA buffer (20mM NAP, pH7.4, 150mM NaCl, 1% Triton, 0.5% sodium-
deoxycholate and 1% SDS) supplemented with protease inhibitors and 10mM
N-ethylmaleimide. The lysates were sonicated, boiled at 95 C for 5min, diluted in
RIPA buffer containing 0.1% SDS and centrifuged at 4 C (16 103g for 15min).
The supernatant was incubated with specific antibodies and protein A-Sepharose
for 3 h at 4 C. After extensive washing, bound proteins were eluted with 2 SDS
sample buffer and separated on SDS–PAGE followed by western blotting47. For the
detection of TbRII ubiquitination, cells were treated with the lysosome inhibitor
bafilomycin A1 (1mM) for 6 h before they were collected for the ubiquitination
assay.
Cellular fractions. Cytosolic, membrane and nuclear fractions were prepared
using the ProteoExtract kit (Calbiochem) according to the manufacturer’s
instructions.
Pulse chase. As previously described46, cells were plated in six-well plates.
Cells were starved for 3 h in Met/Cys-free medium and pulsed for 40min with
200mCiml 1 of 35SMet/Cys. After two washes, the cells were chased in medium
supplemented with cold (unlabelled) Met and Cys (100 mgml 1) before collecting.
Endogenous proteins were collected from the extracts by immunoprecipitation,
then were resolved by SDS–PAGE and visualized by autoradiography. Each
experiment was performed in duplicate.
Mass spectrometry. SDS–PAGE gels were minimally stained with Coomassie
brilliant blue, cut into six molecular weight ranges based on heavy-chain IgG
bands, and digested with trypsin. Immunocomplexes were identified on a Thermo
Fisher LTQ (majority) or Velos-Orbitrap mass spectrometer. Spectral data were
then searched against the human protein RefSeq database in BioWorks or the
Proteome Discoverer Suites using either SeQuest (for LTQ data) or Mascot
(Orbitrap data) software. The immunoprecipitation–mass spectrometry results
were transferred into a FileMaker-based relational database generated in-house,
where protein identification numbers (protein GIs) were converted to GeneID
identifiers according to the NCBI ‘gene accession’ table31.
Immunofluorescence. For the EMT assay, HaCaT cells were plated onto collagen
I-coated coverslips. After adhesion, the cells were serum starved overnight and
either left untreated or treated 36 h with TGF-b (2 ngml 1) in 2% fetal bovine
serum. Cells were fixed for 10min in 4% paraformaldehyde in PBS, permeabilized
with 0.2% TritonX100-PBS and then blocked with 3% bovine serum albumin
(BSA) in PBS for 30min at room temperature. Anti-E-cadherin (BD Transduction
Laboratories) was used at a dilution of 1:1,000 in 3% BSA-PBS and incubated for
3 h at room temperature. Secondary, AlexaFluor488-labelled anti-mouse antibody
(Molecular Probes) was used at a dilution of 1:200 in 3% BSA-PBS, together
with Phalloidin (Molecular Probes) and incubated for 1 h at room temperature.
Coverslips were mounted with 40,6-diamidino-2-phenylindole-containing
VECTASHIELD mounting medium (Vector Laboratories Inc.). Fluorescence was
recorded using a Zeiss Axioplan microscope.
For localization, HeLa cells were transfected with target plasmids and then
processed as described above with a specific primary antibody and secondary
AlexaFluor488-labelled and AlexaFluor593-labelled anti-rabbit antibodies
(Molecular Probes).
Three-dimensional spheroid invasion assays. Semi-confluent MCF10A-RAS
(MII) cells were trypsinized, counted and re-suspended in medium containing
2.4mgml 1 methylcellulose (Sigma) at a concentration of 104 cells per ml. A total
of 100ml of suspension was added into each well of a U-bottom 96-well-plate,
allowing for the formation of one spheroid per well. All spheroids consisted of
103 cells. Two days after plating, the spheroids were collected and embedded into
collagen. A flat-bottom 96-well-plate was coated with neutralized bovine collagen-I
(PureCol, Advanced BioMatrix) according to the manufacturer’s protocol.
Single spheroids were embedded in a 1:1 mix of neutralized collagen and medium
supplemented with 12mgml 1 of methylcellulose. TGF-b (2 ng l 1) was directly
added to the embedding solution. Invasion was monitored over the subsequent 2
days and quantified by measuring the area occupied by the cells using ImageJ
software. Images were captured at days 0, 1 and 1.5 after embedding.
Migration assays. Transwell assays were performed in 24-well PET inserts
(Falcon 8.0-mm pore size) for migration assays. MDA-MB-231 cells with targeted
gene manipulations were serum starved overnight. Then, 5 104 or 10 104 cells
were plated in transwell inserts (at least three replicas for each sample) and left
treated with or without TGF-b (5 ngml 1) for 8 h. Cells in the upper part of the
transwells were removed with a cotton swab; migrated cells were fixed in 4%
paraformaldehyde and stained with 0.5% crystal violet. The filters were imaged,
and the total number of cells was counted. Every experiment was repeated at least
three times independently.
Purification of bacterially expressed recombinant FAF1 proteins. GST-FAF1 wt
and mutant expression constructs were generated by sub-cloning into pGEX-4T1
vectors. Plasmids were used to transform the Escherichia coli strains BL21 and
Rosetta, respectively. Cultures were grown overnight at 37 C. The next day, the
cultures were diluted 1:50 in fresh Luria Bertani medium and grown at 37 C to an
OD600 of 0.6. The cells were then induced overnight at 24 C in the presence of
0.5mM isopropyl-b-D-thiogalactopyranoside, 20mM HEPES pH 7.5, 1mM MgCl2
and 0.05% glucose. For purification, the washed pellets were resuspended in lysis
buffer (PBS, 0.5M NaCl, complete protease inhibitors (Roche), 1mM
phenylmethanesulfonyl fluoride, 1% Triton X-100). After sonication and a
freeze–thaw step, the supernatants of the cell lysates were incubated with
glutathione Sepharose beads (GE Healthcare). The beads were washed twice with
lysis buffer and three times with 50mM Tris-HCl pH 7.5, 0.5M NaCl. Purified
proteins were eluted in 50mM Tris-HCl pH 7.5, 0.5M NaCl and 20mM glu-
tathione. For protein purification, GST was removed using biotin-tagged thrombin.
Immunohistochemical staining and evaluation. Formalin-fixed paraffin-
embedded microarrays of breast cancer tissues were obtained from US Biomax
(BC081120). Primary antibodies specific to p-SMAD2 (1:50; Cell Signalling 3108),
FAF1 (1:200; Bethyl), TbRII (1:100; Santa Cruz) and p-Akt Ser 473 (1:200; Cell
Signalling #9271) were used for immunohistochemical staining. The quantification
of staining was expressed as an H score. The H score was determined by the
formula 3 the percentage of strongly staining cellsþ 2 the percentage of
moderately staining cellsþ the percentage of weakly staining cells, yielding a range
of 0 to 300.
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Statistical analyses. Statistical analyses were performed with a two-tailed
unpaired t-test or as indicated in the legends. P value is indicated by asterisks in the
Figures: *Po0.05; **Po0.01; ***Po0.001. Differences at P¼ 0.05 and lower were
considered significant.
Genotyping of Faf1 / mice, cDNA screen and migration/invasion assays.
Associated references are available in the Supplementary Information.
Data availability. The authors declare that all data supporting the findings of this
study are available within the article and its Supplementary Information files.
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